IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma.
Alphavirus
Semliki Forest virus
anti-PD1
anti-tumor T cells
cancer immunotherapy
glioblastoma
immune checkpoint inhibitors
oncolytic virotherapy
type I interferon
Journal
Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776
Informations de publication
Date de publication:
25 Jun 2021
25 Jun 2021
Historique:
received:
07
06
2020
accepted:
14
03
2021
entrez:
19
4
2021
pubmed:
20
4
2021
medline:
20
4
2021
Statut:
epublish
Résumé
Oncolytic virotherapy holds promise of effective immunotherapy against otherwise nonresponsive cancers such as glioblastoma. Our previous findings have shown that although oncolytic Semliki Forest virus (SFV) is effective against various mouse glioblastoma models, its therapeutic potency is hampered by type I interferon (IFN-I)-mediated antiviral signaling. In this study, we constructed a novel IFN-I-resistant SFV construct, SFV-AM6, and evaluated its therapeutic potency
Identifiants
pubmed: 33869741
doi: 10.1016/j.omto.2021.03.008
pii: S2372-7705(21)00041-3
pmc: PMC8042242
doi:
Types de publication
Journal Article
Langues
eng
Pagination
37-46Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
J Virol Methods. 2008 Mar;148(1-2):265-70
pubmed: 18054090
Int J Cancer. 2014 Sep 15;135(6):1381-9
pubmed: 24347514
Proc Natl Acad Sci U S A. 2018 Oct 30;115(44):E10457-E10466
pubmed: 30322911
Cell Death Dis. 2020 Jan 22;11(1):48
pubmed: 31969562
Clin Cancer Res. 2017 Mar 15;23(6):1519-1530
pubmed: 27637889
Neuro Oncol. 2018 Sep 3;20(10):1383-1392
pubmed: 29762717
Onco Targets Ther. 2016 May 04;9:2627-37
pubmed: 27226725
J Clin Oncol. 2018 May 10;36(14):1419-1427
pubmed: 29432077
N Engl J Med. 2018 Jul 12;379(2):150-161
pubmed: 29943666
Immunity. 2018 Apr 17;48(4):716-729.e8
pubmed: 29625895
J Virol. 2013 Jan;87(1):335-44
pubmed: 23077310
Cytometry A. 2011 Feb;79(2):167-74
pubmed: 21265010
Mol Ther. 2012 Aug;20(8):1529-39
pubmed: 22434140
Oncolytic Virother. 2019 Oct 24;8:27-37
pubmed: 31750274
Front Immunol. 2018 Sep 27;9:2129
pubmed: 30356906
Nat Commun. 2020 Jun 24;11(1):3187
pubmed: 32581235
Nature. 2020 Jan;577(7792):689-694
pubmed: 31942068
Int J Cancer. 2015 Mar 1;136(5):E313-25
pubmed: 25208916
Neuro Oncol. 2017 Nov 6;19(suppl_5):v1-v88
pubmed: 29117289
J Virol. 2018 Sep 12;92(19):
pubmed: 29997212
Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1576-81
pubmed: 20080710
PLoS One. 2012;7(1):e29653
pubmed: 22242177
PLoS Pathog. 2018 Mar 22;14(3):e1006864
pubmed: 29566066
PLoS Pathog. 2018 Jan 29;14(1):e1006835
pubmed: 29377936
J Immunol. 2018 Jul 1;201(1):264-277
pubmed: 29752314
J Virol. 2015 Aug;89(15):7536-49
pubmed: 25972559
JCI Insight. 2018 Apr 19;3(8):
pubmed: 29669928
Mol Ther. 2017 Dec 6;25(12):2620-2634
pubmed: 28967558
PLoS One. 2010 Jan 06;5(1):e8603
pubmed: 20066051
Nat Rev Immunol. 2014 Jan;14(1):36-49
pubmed: 24362405
Oncoimmunology. 2018 Sep 5;7(12):e1501137
pubmed: 30524896
J Transl Med. 2014 Apr 29;12:107
pubmed: 24779345
Cancer Cell. 2018 Apr 9;33(4):599-605
pubmed: 29634947
Neuropathology. 2011 Aug;31(4):376-83
pubmed: 21134002
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
J Virol. 2015 Oct;89(20):10637-47
pubmed: 26269187